Single infusion of anti-CD19 CAR T-cells confers high response rate in aggressive non-Hodgkin lymphoma – Healio
|
Single infusion of anti-CD19 CAR T-cells confers high response rate in aggressive non-Hodgkin lymphoma
Healio The ZUMA-1 trial designed to evaluate axicabtagene ciloleucel in patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma met its primary endpoint of overall response rate, according to the drug's manufacturer. |
